Kala Bio Finalizes Exclusive U.S. Distribution Deal for Ophthalmology Genetic Testing
KALA is trading near its 52-week low of $0.503 (7.0% above the low).
Summary
Kala Bio has converted its September 1 letter of intent with Virotek into a definitive exclusive U.S. distribution agreement for Virotek's ophthalmology genetic testing program. The one-year exclusivity is contingent on Kala hitting commercial milestones, and the companies will share profits after Virotek recoups program costs. Kala also gets a right of first refusal on certain Virotek ophthalmology products and a framework to expand into oncology, preventive health, telehealth, and white-label channels. This is a meaningful step for a company with a market cap around $10 million and cash under $0.1 million, as it adds a potential revenue stream without upfront capital. However, no revenue projections are provided, and Kala faces Nasdaq delisting and going-concern risks. The deal's success hinges on Kala's ability to execute commercially while managing its liquidity constraints.
At the time of this announcement, KALA was trading at $0.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.1M. The 52-week trading range was $0.50 to $1,030.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.